Premium
Recent results of multimodal therapy of gastric lymphoma
Author(s) -
Shiu Man H.,
Nisce Lourdes Z.,
Pinna Antonio,
Straus David J.,
Tome Michael,
Filippa Daniel A.,
Lee Burton J.
Publication year - 1986
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19861001)58:7<1389::aid-cncr2820580702>3.0.co;2-y
Subject(s) - medicine , vincristine , chop , surgery , cyclophosphamide , chemotherapy , prednisone , cancer , radiation therapy , regimen , gastroenterology , lymphoma , stomach , abdomen , stage (stratigraphy) , paleontology , biology
The efficacy of multimodality treatment of gastric lymphoma was examined in a retrospective study of 46 patients treated at the Memorial Sloan‐Kettering Cancer Center from 1971 to 1982. The principal treatment plan consisted of (1) surgical resection of the gastric lymphoma (n = 36) where feasible, followed by (2) radiation therapy of the whole abdomen (n = 23) with a boosting dose to the stomach‐bed to 3700 cGy, and/or (3) chemotherapy using mainly the CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) regimen as an adjuvant (n = 7), or CHOP plus other drugs for advanced disease. The median follow‐up time of patients was 61 months (range, 30 months to 14 years). There was no operative mortality. No patient developed known relapse in the abdomen after resection and total abdominal irradiation, and none suffered relapses after adjuvant chemotherapy, for Stages I‐E and II‐E. At 5 years, the estimated survival rate after treatment was 95%, 78%, and 25%, respectively for Stages I‐E (n = 20), II‐E (n = 9) and IV (n = 17). The results for Stage I‐E and II‐E resectable tumors were significantly improved ( P < 0.05 and < 0.1 respectively) over those of similar tumors treated in 1949 to 1970.